Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? - 19/04/17
![](/templates/common/images/mail.png)
Abstract |
Atopic dermatitis (AD) is a paradigmatic chronic inflammatory skin disease characterized by a complex pathophysiology and a wide spectrum of the clinical phenotype. Despite this high degree of heterogeneity, AD is still considered a single disease and usually treated according to the “one-size-fits-all” approach. Thus more tailored prevention and therapeutic strategies are still lacking. As for other disciplines, such as oncology or rheumatology, we have to approach AD in a more differentiated way (ie, to dissect and stratify the complex clinical phenotype into more homogeneous subgroups based on the endophenotype [panel of biomarkers]) with the aim to refine the management of this condition. Because we are now entering the era of personalized medicine, a systems biology approach merging the numerous clinical phenotypes with robust (ie, relevant and validated) biomarkers will be needed to best exploit their potential significance for the future molecular taxonomy of AD. This approach will not only allow an optimized prevention and treatment with the available drugs but also hopefully help assign newly developed medicinal products to those patients who will have the best benefit/risk ratio.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis, clinical phenotype, endophenotype, biomarkers, stratified medicine, precision medicine
Abbreviation used : AD
Plan
Disclosure of potential conflict of interest: T. Bieber serves on the board for Sanofi/Regeneron, serves as a consultant for Sanofi/Regeneron, receives payments for lectures from Sanofi/Regeneron, and receives payment for educational presentation from Sanofi/Regeneron. A. M. D'Erme serves as a consultant for La Roche Posay. C. A. Akdis serves as a consultant form Actellion, Aventis, Stallergenes, Allergopharma, and Circacia; is an employee of the Swiss Institute of Allergy and Asthma Research, University of Zurich; receives grant support from Novartis, PREDICTA: European Commission's Seventh Framework Programme, the Swiss National Science Foundation Research, MeDALL: European Commission's Seventh Framework Programme, and the Christine Kühne–Center for Allergy Research (CK-CARE). C. Traidl-Hoffmann receives grants support from the CK-CARE Center of Allergy Research and Education. R. Lauener receives grant support and travel support from the Kühne Foundation; serves as a consultant for AstraZeneca; and receives support from Meda, Menarini, Nestlé, Vifor, and ALK-Abelló. P. Schmid-Grendelmeier serves as a consultant for Sanofi AG. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 139 - N° 4S
P. S58-S64 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?